½ÃÀ庸°í¼­
»óǰÄÚµå
1395033

Àü°Ô³ð ½ÃÄö½º ½ÃÀå : Á¦Ç°¡¤¼­ºñ½ºº°, À¯Çüº°, ±â¼úº°, ¿ëµµº°, ÃÖÁ¾»ç¿ëÀÚº°, ¼¼°è ¿¹Ãø(2023-2032³â)

Whole Genome Sequencing Market - By Products & Services, By Type, Technology, Application, End-user, Global Forecast, 2023- 2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Global Market Insights Inc. | ÆäÀÌÁö Á¤º¸: ¿µ¹® 200 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ Àü°Ô³ð ½ÃÄö½º ½ÃÀåÀº ½ÅÈï ±¹°¡ÀÇ °Ô³ð ¿¬±¸°³¹ß ±¸»óÀÇ ±ÞÁõ¿¡ ÀÇÇØ 2023-2032³â 18.7%ÀÇ CAGRÀ» ±â·ÏÇÕ´Ï´Ù. ÀÌ ±¹°¡¿¡¼­´Â °Ô³ð ¿¬±¸¿¡ ´ëÇÑ ÅõÀÚ¿Í ÁßÁ¡ÀÌ ³ô¾ÆÁö°í ÀÖÀ¸¸ç, Àü°Ô³ð ½ÃÄö½º ±â¼úÀÇ Ã¤ÅÃÀÌ °¡¼ÓÇϰí ÀÖ½À´Ï´Ù.

¿¹¸¦ µé¾î 2023³â 11¿ù ¿µ±¹ ¹ÙÀÌ¿À¹ðÅ©(UK Biobank)´Â ÀÇÇÐ ¿¬±¸ÀÇ È¹±âÀûÀÎ ¹ßÀüÀ¸·Î 50¸¸ ¸íÀÇ ´ë±Ô¸ð Âü¿©ÀÚÀÇ ÀüÀå À¯Àüü ¿°±â¼­¿­À» ÅëÇØ ¾òÀº ȹ±âÀûÀÎ »õ·Î¿î µ¥ÀÌÅ͸¦ ¹ßÇ¥Çß½À´Ï´Ù. ÀÌ ±â³äºñÀûÀÎ ¼º°ú´Â »õ·Î¿î Áø´Ü, Ä¡·á¹ý ¹× ÀáÀçÀû Ä¡·á¹ý ¹ß°ß¿¡ Çõ¸íÀ» ÀÏÀ¸Å³ °ÍÀÔ´Ï´Ù. ƯÈ÷ ÀÌ µ¥ÀÌÅÍ´Â °³ÀÎ ½Äº°ÀÌ °¡´ÉÇÑ Á¤º¸¸¦ »èÁ¦Çϰí ÇÁ¶óÀ̹ö½Ã¸¦ öÀúÈ÷ º¸È£ÇÏ´Â ¾ÈÀüÇÑ µ¥ÀÌÅͺ£À̽º¸¦ ÅëÇØ ¼¼°è ½ÂÀÎµÈ ¿¬±¸Àڵ鸸 Á¢±ÙÇÒ ¼ö ÀÖ´Ù´Â Á¡ÀÌ ÁÖ¸ñÇÒ ¸¸ÇÕ´Ï´Ù. 5³â¿¡ °ÉÄ£ öÀúÇÑ ³ë·Â ³¡¿¡ ¸¶Ä§³» ¼¼°è¿¡¼­ °¡Àå ±¤¹üÀ§ÇÑ ¿°±â¼­¿­ µ¥ÀÌÅÍ Ä÷º¼ÇÀ» °ø°³ÇßÀ¸¸ç, ±× ¹üÀ§¿Í ¾ß¸Á¿¡ ÀÖÀ¸¸ç, Àü·Ê ¾ø´Â ÇÁ·ÎÁ§Æ®ÀÇ Áý´ë¼ºÀÔ´Ï´Ù.

Á¤¹ÐÀÇ·á, ³ó¾÷, »ý¸í°øÇÐ ºÐ¾ßÀÇ ¹ßÀüÀº °¢±¹ÀÌ ´Ù¾çÇÑ ¿ëµµ·Î À¯Àüü µ¥ÀÌÅ͸¦ Ȱ¿ëÇϸ鼭 ÀÌ·¯ÇÑ ±Þ°ÝÇÑ Áõ°¡¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¼¼°è ¿¬±¸ ´Üü °£ÀÇ °øµ¿ ¿¬±¸ È®´ë¿Í ½ÅÈï ±¹°¡ÀÇ À¯ÀüüÇÐ »óȲÀÇ È®´ë´Â ÀüüÀûÀ¸·Î Àüü °Ô³ð ½ÃÄö½Ì ½ÃÀå ¼ö¿ä¸¦ ÃËÁøÇÏ°í °úÇÐÀû ޱ¸¿Í Çõ½ÅÀÇ ¹Ì·¡¸¦ Çü¼ºÇÒ °ÍÀÔ´Ï´Ù.

Á¤¹ÐÀÇ·á ºÐ¾ß´Â 2023-2032³â »çÀÌ¿¡ °ý¸ñÇÒ ¸¸ÇÑ ¹ßÀüÀ» ÀÌ·ê °ÍÀÔ´Ï´Ù. ÇコÄɾ °³ÀÎ ¸ÂÃãÇü Ä¡·á Àü·«À¸·Î ÀüȯÇϸ鼭 ÀüÀå À¯Àüü ¿°±â¼­¿­ ºÐ¼®ÀÌ Ãʼ®À¸·Î ºÎ»óÇÒ °ÍÀÔ´Ï´Ù. °³ÀÎÀÇ Àüü À¯Àüü ±¸¼ºÀ» ÇØµ¶ÇÒ ¼ö ÀÖ´Â ´É·ÂÀº ¸ÂÃãÇü ÀÇ·á °³ÀÔ, Áúº´ À§Çè ¿¹Ãø ¹× Ä¡·á ÃÖÀûÈ­¸¦ °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. Ç¥ÀûÄ¡·á¿Í ¿¹¹æÀÇÇп¡ ÃÊÁ¡À» ¸ÂÃá ÀüÀåÀ¯Àüü ½ÃÄö½Ì ½ÃÀå Á¡À¯À²Àº ÀüÀåÀ¯Àüü ½ÃÄö½Ì ±â¼ú¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, Áø´Ü°ú Ä¡·áÀÇ °³ÀÎÈ­¸¦ ÅëÇØ ÀÇ·á¿¡ Çõ¸íÀ» ÀÏÀ¸Å°°í ȯÀÚ °á°ú¸¦ °³¼±ÇÏ´Â °ÍÀ» ¸ñ°ÝÇϰí ÀÖ½À´Ï´Ù.

º´¿ø ¹× Ŭ¸®´Ð ºÎ¹®Àº 2023-2032³â ÁÖ¸ñÇÒ ¸¸ÇÑ CAGRÀ» ±â·ÏÇÒ °ÍÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ÀÇ·á ½Ã¼³µéÀÌ Á¤¹ÐÀÇ·á¿Í °³ÀÎ ¸ÂÃãÇü ÀǷḦ ¿ì¼±½ÃÇÏ´Â °¡¿îµ¥, ÀüÀåÀ¯Àüü ½ÃÄö½ÌÀÌ °ÔÀÓ Ã¼ÀÎÀú·Î ºÎ»óÇϰí ÀÖ½À´Ï´Ù. »ó¼¼ÇÑ À¯ÀüÀû ÀλçÀÌÆ®À» Á¦°øÇÏ´Â ÀÌ ±â¼úÀÇ ´É·ÂÀº Èñ±ÍÁúȯÀ» ½Äº°Çϰí, Ä¡·á ¹æÄ§À» °áÁ¤Çϰí, Áúº´ °¨¼ö¼ºÀ» ¿¹ÃøÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ¸ÂÃãÇü Ä¡·á¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ º´¿ø ¹× Ŭ¸®´ÐÀº À¯Àüü ½ÃÄö½Ì ½ÃÀåÀÇ ¼ºÀåÀ» ÁÖµµÇϰí ÀÖÀ¸¸ç, º¸´Ù Á¤È®ÇÑ Áø´Ü°ú ÃÖÀûÀÇ Ä¡·á¸¦ À§ÇØ À¯ÀüÀÚ Á¤º¸¸¦ ȯÀÚ Ä¡·á¿¡ ÅëÇÕÇÔÀ¸·Î½á ÀÇ·á ¼­ºñ½º Á¦°ø¿¡ Çõ¸íÀ» ÀÏÀ¸Å°°í ÀÖ½À´Ï´Ù.

À¯·´ÀÇ Àüü °Ô³ð ½ÃÄö½Ì »ê¾÷Àº 2023-2032³â °ý¸ñÇÒ ¸¸ÇÑ CAGRÀ» º¸ÀÏ °ÍÀÔ´Ï´Ù. Á¤¹ÐÀÇ·á¿Í À¯Àüü ¿¬±¸¿¡ ÁßÁ¡À» µÐ À¯·´ ±¹°¡µéÀº À¯ÀüÀÚ µ¥ÀÌÅ͸¦ ÀÓ»ó Áø·á¿¡ ÅëÇÕÇÏ´Â ±¸»óÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. °³ÀÎ ¸ÂÃãÇü ÀǷḦ Áß½ÃÇÏ´Â ÀÌ Áö¿ªÀº º´¿ø, ¿¬±¸±â°ü ¹× Ŭ¸®´Ð¿¡¼­ ÀüÀå À¯Àüü ½ÃÄö½Ì ±â¼úÀÇ Ã¤ÅÃÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¼ö¿ä ±ÞÁõÀº ¸ÂÃãÇü Áø´Ü°ú Ä¡·á¸¦ À§ÇØ À¯ÀüÀû ÀλçÀÌÆ®À» Ȱ¿ëÇÏ·Á´Â À¯·´ÀÇ ³ë·ÂÀ» ¹Ý¿µÇϰí ÀÖÀ¸¸ç, ÁøÈ­ÇÏ´Â ÇコÄÉ¾î ÆÐ·¯´ÙÀÓ ¼Ó¿¡¼­ ½ÃÀåÀ» ¹ßÀü½Ã۰í ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú Á¶»ç ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå Àü°Ô³ð ½ÃÄö½º ½ÃÀå ÀλçÀÌÆ®

  • ¿¡ÄڽýºÅÛ ºÐ¼®
  • ¾÷°è¿¡ ´ëÇÑ ¿µÇâ¿äÀÎ
    • ÃËÁø¿äÀÎ
    • ¾÷°èÀÇ ÀáÀçÀû ¸®½ºÅ© ¹× °úÁ¦
  • ¼ºÀå °¡´É¼º ºÐ¼®
  • COVID-19 ¿µÇ⠺м®
  • ±ÔÁ¦ »óȲ
  • PorterÀÇ »ê¾÷ ºÐ¼®
  • PESTEL ºÐ¼®

Á¦4Àå °æÀï ±¸µµ

  • ¼­·Ð
  • ±â¾÷ ¸ÅÆ®¸¯½º ºÐ¼®
  • ÁÖ¿ä ½ÃÀå ±â¾÷ÀÇ °æÀï ºÐ¼®
  • °æÀï Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º
  • Àü·« ´ë½Ãº¸µå

Á¦5Àå Àü°Ô³ð ½ÃÄö½º ½ÃÀå ÃßÁ¤¡¤¿¹Ãø : Á¦Ç°¡¤¼­ºñ½ºº°(2018-2032³â)

  • ÁÖ¿ä µ¿Çâ : Á¦Ç°¡¤¼­ºñ½ºº°
  • ±â±â
  • ¼Ò¸ðǰ
  • ¼­ºñ½ºº°

Á¦6Àå Àü°Ô³ð ½ÃÄö½º ½ÃÀå ÃßÁ¤¡¤¿¹Ãø : À¯Çüº°(2018-2032³â)

  • ÁÖ¿ä µ¿Çâ : À¯Çüº°
  • ´ë±Ô¸ð Àü°Ô³ð ½ÃÄö½º
  • ¼Ò±Ô¸ð Àü°Ô³ð ½ÃÄö½º

Á¦7Àå Àü°Ô³ð ½ÃÄö½º ½ÃÀå ÃßÁ¤¡¤¿¹Ãø : ±â¼úº°(2018-2032³â)

  • ÁÖ¿ä µ¿Çâ : ±â¼úº°
  • »ý¾î ½ÃÄö½º
  • ÁßÇÕÈ¿¼Ò ¿¬¼â ¹ÝÀÀ
  • ¸¶ÀÌÅ©·Î¾î·¹ÀÌ
  • Â÷¼¼´ë ½ÃÄö½º
  • ±âŸ ±â¼ú

Á¦8Àå Àü°Ô³ð ½ÃÄö½º ½ÃÀå ÃßÁ¤¡¤¿¹Ãø : ¿ëµµº°(2018-2032³â)

  • ÁÖ¿ä µ¿Çâ : ¿ëµµº°
  • Áø´Ü
  • Drug Discovery ¹× ÀǾàǰ °³¹ß
  • Á¤¹ÐÀÇ·á
  • ±âŸ ¿ëµµ

Á¦9Àå Àü°Ô³ð ½ÃÄö½º ½ÃÀå ÃßÁ¤¡¤¿¹Ãø : ÃÖÁ¾»ç¿ëÀÚº°(2018-2032³â)

  • ÁÖ¿ä µ¿Çâ : ÃÖÁ¾»ç¿ëÀÚº°
  • º´¿ø¡¤Å¬¸®´Ð
  • Çмú±â°ü¡¤¿¬±¸¼Ò
  • Á¦¾à¡¤¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷
  • ±âŸ ÃÖÁ¾»ç¿ëÀÚ

Á¦10Àå Àü°Ô³ð ½ÃÄö½º ½ÃÀå ÃßÁ¤¡¤¿¹Ãø : Áö¿ªº°(2018-2032³â)

  • ÁÖ¿ä µ¿Çâ : Áö¿ªº°
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ÀÌÅ»¸®¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • È£ÁÖ
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦11Àå ±â¾÷ °³¿ä

  • Thermo Fisher Scientific, Inc
  • Danaher Corporation
  • Illumina, Inc
  • QIAGEN N.V.
  • Merck KGaA
  • Eurofins Scientific
  • Siemens Healthineers
  • Macrogens, Inc
  • Bio-Rad Laboratories, Inc
  • Agilent Technologies, Inc
  • F. Hoffmann-La Roche Ltd
KSA 23.12.21

Global Whole Genome Sequencing Market will witness 18.7% CAGR between 2023 and 2032 due to burgeoning research and development initiatives in genomics from emerging nations. These countries' increased investment and focus on genomic studies accelerate the adoption of whole genome sequencing technologies.

For instance, in November 2023, in a groundbreaking stride for medical research, UK Biobank unveiled groundbreaking new data resulting from whole genome sequencing involving its vast pool of half a million participants. This monumental achievement is poised to revolutionize the discovery of novel diagnostics, treatments, and potential cures. Notably, this treasure trove of data is accessible exclusively to approved researchers worldwide through a secure database that meticulously safeguards privacy by removing identifiable information. After an exhaustive five-year endeavor, surpassing 350,000 hours of genome sequencing and backed by an investment exceeding £200 million, UK Biobank finally released the world's most extensive collection of sequencing data, marking the culmination of an unprecedented project in its scope and ambition.

Advancements in precision medicine, agriculture, and biotechnology drive this surge as nations harness genomic data for diverse applications. The growing collaboration between global research entities and the expanding genomics landscape in emerging nations collectively propel the whole genome sequencing market demand, shaping the future of scientific exploration and innovation.

The overall Whole Genome Sequencing Market is classified based on application, end-user, and region.

Precision medicine segment will undergo significant development from 2023 to 2032. As healthcare shifts towards personalized treatment strategies, whole genome sequencing emerges as a cornerstone. Its ability to decode an individual's complete genetic makeup enables tailored medical interventions, predicting disease risks and optimizing therapies. With a focus on targeted treatments and preventive care, the whole genome sequencing market share witnesses escalated demand for whole genome sequencing technologies, revolutionizing healthcare by individualizing diagnostics and treatments for enhanced patient outcomes.

Hospitals and clinics segment will register a noteworthy CAGR from 2023 to 2032. As these healthcare facilities prioritize precision medicine and personalized care, whole genome sequencing emerges as a game-changer. The technology's ability to uncover detailed genetic insights aids in identifying rare diseases, guiding treatment decisions, and predicting disease susceptibility. With a growing emphasis on tailored therapies, hospitals, and clinics increasingly propel whole genome sequencing market growth, revolutionizing healthcare delivery by integrating genetic information into patient care for more accurate diagnoses and optimized treatments.

Europe whole genome sequencing industry will showcase a commendable CAGR from 2023 to 2032. With a focus on precision medicine and genomic research, European countries spearhead initiatives to integrate genetic data into clinical practice. The region's emphasis on personalized healthcare drives the adoption of whole genome sequencing technologies in hospitals, research institutions, and clinics. This demand surge reflects Europe's commitment to harnessing genetic insights for tailored diagnostics and treatments, propelling the market forward amidst a landscape of evolving healthcare paradigms.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market definition
  • 1.2 Base estimates & calculations
  • 1.3 Forecast calculation
  • 1.4 Covid-19 impact analysis at global level
  • 1.5 Data validation
  • 1.6 Data sources
    • 1.6.1 Primary
    • 1.6.2 Secondary
      • 1.6.2.1 Paid sources
      • 1.6.2.2 Public sources

Chapter 2 Executive Summary

  • 2.1 Global whole genome sequencing market 360 degree synopsis, 2018 - 2032 (USD Million)
    • 2.1.1 Business trends
    • 2.1.2 Regional trends
    • 2.1.3 Products & services trends
    • 2.1.4 Type trends
    • 2.1.5 Technology trends
    • 2.1.6 Application trends
    • 2.1.7 End-user trends

Chapter 3 Whole Genome Sequencing Market Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising cases of cancer
      • 3.2.1.2 Advancement in sequencing technologies
      • 3.2.1.3 Increasing demand for whole genome sequencing for genome mapping programs
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 Lack of standardization in sequencing techniques
  • 3.3 Growth potential analysis
    • 3.3.1 By products & services
    • 3.3.2 By type
    • 3.3.3 By technology
    • 3.3.4 By application
    • 3.3.5 By end-users
  • 3.4 COVID-19 impact analysis
  • 3.5 Regulatory landscape
  • 3.6 Porter's analysis
  • 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2022

  • 4.1 Introduction
  • 4.2 Company matrix analysis, 2022
  • 4.3 Competitive analysis of major market players, 2022
  • 4.4 Competitive positioning matrix, 2022
  • 4.5 Strategic dashboard, 2022

Chapter 5 Whole Genome Sequencing Market Estimates and Forecast, By Products & Services, 2018 - 2032 (USD Million)

  • 5.1 Key trends, by products & services
  • 5.2 Instruments
  • 5.3 Consumables
  • 5.4 Services

Chapter 6 Whole Genome Sequencing Market Estimates and Forecast, By Type, 2018 - 2032 (USD Million)

  • 6.1 Key trends, by type
  • 6.2 Large whole genome sequencing
  • 6.3 Small whole genome sequencing

Chapter 7 Whole Genome Sequencing Market Estimates and Forecast, By Technology, 2018 - 2032 (USD Million)

  • 7.1 Key trends, by technology
  • 7.2 Sanger sequencing
  • 7.3 Polymerase chain reaction
  • 7.4 Microarray
  • 7.5 Next Generation Sequencing
  • 7.6 Other technologies

Chapter 8 Whole Genome Sequencing Market Estimates and Forecast, By Application, 2018 - 2032 (USD Million)

  • 8.1 Key trends, by application
  • 8.2 Diagnostics
  • 8.3 Drug discovery and development
  • 8.4 Precision medicine
  • 8.5 Other applications

Chapter 9 Whole Genome Sequencing Market Estimates and Forecast, By End-user, 2018 - 2032 (USD Million)

  • 9.1 Key trends, by end-user
  • 9.2 Hospitals & clinics
  • 9.3 Academic institutes & research centers
  • 9.4 Pharmaceutical and biotechnology companies
  • 9.5 Other end-users

Chapter 10 Whole Genome Sequencing Market Estimates and Forecast, By Region, 2018 - 2032 (USD Million)

  • 10.1 Key trends, by region
  • 10.2 North America
    • 10.2.1 U.S.
    • 10.2.2 Canada
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 France
    • 10.3.4 Spain
    • 10.3.5 Italy
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 China
    • 10.4.2 Japan
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 Rest of Asia Pacific
  • 10.5 Latin America
    • 10.5.1 Brazil
    • 10.5.2 Mexico
    • 10.5.3 Rest of Latin America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 South Africa
    • 10.6.3 Rest of Middle East & Africa

Chapter 11 Company Profiles

  • 11.1 Thermo Fisher Scientific, Inc
  • 11.2 Danaher Corporation
  • 11.3 Illumina, Inc
  • 11.4 QIAGEN N.V.
  • 11.5 Merck KGaA
  • 11.6 Eurofins Scientific
  • 11.7 Siemens Healthineers
  • 11.8 Macrogens, Inc
  • 11.9 Bio-Rad Laboratories, Inc
  • 11.10 Agilent Technologies, Inc
  • 11.11 F. Hoffmann-La Roche Ltd
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦